BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the closing of the acquisition of the solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility’s assets and ...
4D Biomaterials has just completed a £1.6m ($2.2m) seed investment round led by DSW Ventures and backed by the MEIF Proof of Concept and Early Stage Fund which is managed by Mercia and part of ...
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based COVID–19 vaccine candidate with Matrix-M™ adjuvant. The agreement covers the purchase of up to ...
Popular Posts
